Can­cer care start­up Thyme Care rais­es $60M, beat­ing the odds of rais­ing a Se­ries B dur­ing dig­i­tal health’s fund­ing ...

Last year
Financing
Startups

​​FDA to al­low 23andMe to re­port more BR­CA vari­ants; Janssen se­cures deal with AI-drug dis­cov­ery out­fit

Last year
News Briefing

Am­gen and Hori­zon can close their $28B deal af­ter re­solv­ing law­suit by the FTC

Last year
Deals
Pharma

BioN­Tech, Du­al­i­ty­Bio steer ADC in­to PhI­II, with aim to com­pete in HER2-low sub­group with En­her­tu

Last year
R&D

Bavar­i­an Nordic aban­dons Covid boost­er af­ter da­ta show it's not as ef­fec­tive against new vari­ants

Last year
R&D
Coronavirus

Nex­Im­mune to lay off 53% of em­ploy­ees to save mon­ey, CFO to step down 

Last year
People

David Khougaz­ian joins Flag­ship to build ‘part­ner­ships with dif­fer­ent fla­vors’; For­mer No­vo Nordisk ex­ec to lead ...

Last year
Peer Review

Le­gal ex­perts say some IRA chal­lenges are 'weak­er than oth­er­s'

Last year
Pharma
Law

Lil­ly, No­vo, Sanofi face pres­sure from law­mak­ers to clar­i­fy low-cost in­sulin pro­grams

Last year
Pharma
FDA+

FDA aims to bet­ter in­cen­tivize qual­i­ty drug man­u­fac­tur­ing in new pro­gram

Last year
FDA+
Manufacturing

Alvotech re­sub­mits its in­ter­change­able Hu­mi­ra biosim­i­lar as Ab­b­Vie clings to brand dom­i­nance

Last year
Pharma

Sana lays off staff as cell ther­a­py biotech awaits first clin­i­cal da­ta

Last year
People
Cell/Gene Tx

Stop TB says the price of J&J's tu­ber­cu­lo­sis treat­ment be­daquiline drops 55%

Last year
Pharma

Phar­ma in­dus­try rep­u­ta­tion set­tles in­to ‘new nor­mal’ af­ter good­will from in­sulin price drop fades

Last year
Pharma
Marketing

Mallinck­rodt files for bank­rupt­cy for the sec­ond time, se­cures $150M to con­tin­ue op­er­at­ing

Last year
Pharma

Man­u­fac­tur­ing roundup: Eu­roAPI to ac­quire oligonu­cleotide mak­er for $10M+; EU na­tions face Trulic­i­ty short­age

Last year
Manufacturing

Zevra beefs up rare dis­ease port­fo­lio via $91M ac­qui­si­tion of Ac­er Ther­a­peu­tics

Last year
Deals
R&D

Flag­ship re­fo­cus­es stealth RNA biotech; Mesoblast en­acts pay cuts for ex­ec­u­tives

Last year
News Briefing

As Revlim­id sales fall, Bris­tol My­ers turns to its next mul­ti­ple myelo­ma pill that's a mol­e­c­u­lar glue

Last year
R&D

Sage re­mains tight-lipped on post­par­tum launch plans in wake of re­struc­tur­ing

Last year
People
Pharma

Ot­su­ka to ac­quire psy­che­del­ic drug dis­cov­ery out­fit Mind­set Phar­ma

Last year
Deals

Alk­er­mes, Te­va set­tle patent suit around opi­oid-block­er Viv­it­rol, paving way for gener­ics af­ter three-year fight

Last year
Pharma
Law

Sage shrinks work­force by 40% in light of ma­jor de­pres­sion drug re­jec­tion 

Last year
People
R&D

Ex­clu­sive: Stem cell sci­en­tist and bit.bio founder launch­es new start­up with goal of ex­tend­ing healthspan by 20 years

Last year
Financing
Startups
First page Previous page 287288289290291292293 Next page Last page
A service from the Financial Times